Iron Deficiency Anemia of Pregnancy, Iron Malabsorption
Conditions
Keywords
Iron Deficiency Anemia of Pregnancy, oral iron supplementation, parenteral iron supplementation, maternal anemia
Brief summary
Iron deficiency is the most common cause of anemia in pregnancy worldwide, and, when severe, can have serious consequences for mothers and babies. While treatment of iron-deficiency anemia with iron supplementation is recommended, treatment strategies remain controversial: the American College of Obstetrics and Gynecology recommends oral iron supplementation with parental iron reserved for the rare patient who cannot tolerate or will not take oral iron, while United Kingdom professional organizations recommend a more liberal use of parenteral iron. The reason for these disparate recommendations is that few high-quality studies comparing oral to parenteral iron have been conducted in developed countries, and the potential impact of parental iron treatment on obstetric and perinatal outcomes remains unclear. We propose the first randomized-controlled trial in the United States describing the effectiveness and safety of treating pregnant women with iron-deficiency anemia with a protocol including parenteral iron compared with a protocol based on oral iron.
Detailed description
Iron deficiency is the most common cause of anemia in pregnancy worldwide, and, when severe, can have serious consequences for mothers and babies. In the United States, anemia affects nearly 20% of pregnancies and the majority is iron-deficiency anemia. Therefore, treatment of iron-deficiency anemia with iron supplementation is recommended.1 However, there is controversy about the treatment strategies. The American College of Obstetrics and Gynecology recommends oral iron supplementation for iron-deficiency anemia in pregnancy, with parental iron reserved only for the rare patient who cannot tolerate or will not take oral iron (1) Conversely, guidelines from the United Kingdom. are more liberal on the use of parental iron for the treatment of iron-deficiency anemia in pregnancy (2). Both treatment guidelines are based on limited data regarding the risks and benefits of parental iron for treatment of iron-deficiency anemia in pregnancy. The majority of randomized trials were conducted in developing country settings. In fact, few high-quality studies have been conducted in developed countries, and none has been conducted in the United States Moreover, there is limited data from prior studies on the impact of parental iron treatment on perinatal outcomes. The most recent Cochrane review including mostly from trials conducted in low-income countries found that, although parenteral iron improved hemoglobin levels and iron stores than the oral route, no clinical outcomes were assessed and there were insufficient data on adverse effects (3). The authors concluded that large, good quality trials, assessing clinical outcomes including adverse effects … are required (3). This randomized controlled trial aims to assess the effectiveness and safety of treating pregnant women with iron-deficiency anemia with a protocol including parenteral iron compared with a protocol based on oral iron. We hypothesize that treating iron-deficiency anemia with parental iron is associated with improved maternal and neonatal outcomes compared with a protocol based on oral iron. To increase generalizability of the findings, we will use broad inclusion criteria and analyze data using the intention-to-treat principle.
Interventions
Single intravenous infusion of iron dextran 1000mg.
Oral iron supplementation with ferrous sulfate 325mg one to three times daily
Sponsors
Study design
Masking description
The research team will be blinded to the patients' treatment arm. A team of resident physicians who are unfamiliar with the study aims will provide standard obstetric care to all participants.
Intervention model description
All participants at less than 28 weeks gestation will have an anemia evaluation and work up per standard prenatal care. Those who meet a clinical diagnosis of iron-deficiency anemia will initiate oral iron and have their Complete Blood Count rechecked between 24 and 28 weeks gestation. If their hemoglobin is less than 10 mg/dL, they will be randomized to either continue their oral iron supplementation or receive a single intravenous dextran iron transfusion. If the patient is enrolled after 28 weeks and receives a diagnosis of iron deficiency anemia, she will be randomized at that time.
Eligibility
Inclusion criteria
* Iron-deficiency anemia (serum ferritin \<30 micrograms, normal hemoglobin electrophoresis, and hemoglobin \<10 mg/dL), planned delivery at Barnes-Jewish Hospital
Exclusion criteria
* Non-iron-deficiency anemia, multiple gestation, prenatally diagnosed major fetal anomalies, known aneuploidy, planned delivery at other hospital, inability to obtain consent
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Maternal Anemia at Delivery | At delivery | Number of participants with maternal hemoglobin \<11g/dl at delivery |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Maternal Hemoglobin at Delivery | On admission to inpatient obstetrics unit for delivery | Maternal hemoglobin on admission to inpatient obstetrics unit for delivery |
| Number of Participants With Medication Adverse Events | 2 - 3 days after single intravenous iron infusion or initiation of oral iron | Participants reporting symptoms when contacted by via telephone 2 - 3 days after their infusion of intravenous iron or initiation of oral iron |
| Maternal Hemoglobin Below 10g/dl at Delivery | At delivery | Number of participants with hemoglobin below 10g/dl at delivery |
| Maternal Ferritin at Delivery | At delivery | Maternal serum ferritin level in μg/L at delivery |
| Number of Participants Who Received Blood Transfusion | During inpatient admission for delivery of neonate | Participant receiving transfusion of packed red blood cells during admission for delivery of infant obtained via medical chart review. |
| Mode of Delivery | Once, at infant delivery | Whether infant was delivered vaginally or via cesarean section |
| Birth Weight | Obtained once, at infant delivery | Neonatal weight at delivery |
| Umbilical Cord Arterial pH | Drawn once from umbilical cord segment at delivery | Umbilical cord arterial pH obtained at delivery |
| APGAR Scores at 1 Minutes of Life | Obtained at 1 minute of life | The APGAR score, named after the Virginia Apgar, pediatrician who came up with it, measures the physical condition of a newborn infant on a scale ranging from a minimum of 0 (worsts) to a maximum of 10 (best). |
| Neonatal Hemoglobin | Drawn once from umbilical cord segment at birth | Neonatal hemoglobin in g/dl at delivery |
| Composite Neonatal Morbidity (Defined by the Occurrence of One or More of 10 Neonatal Morbidities. | At birth | Neonatal morbidity composite, defined by the occurrence of one or more of the following neonatal morbidities: neonatal seizures (diagnosed by clinician), intraventricular hemorrhage (diagnosed by clinician on brain MRI or Ultrasound), hypoxic-ischemic encephalopathy (diagnosed by clinician), neonatal hypothermic therapy (brain cooling as documented on inpatient record, sepsis (diagnosed by blood culture), respiratory distress syndrome (diagnosed by clinician), hyperbilirubinemia requiring photo therapy (diagnosed by clinician), birth injury (diagnosed by clinician), or meconium aspiration syndrome (diagnosed by clinician), neonatal intensive care unit admission (documented in the inpatient record). |
| Neonatal Ferritin | Drawn once from umbilical cord segment at birth | Neonatal ferritin in ug/L at delivery |
| Gestational Age at Delivery | Once, at infant delivery | Gestational age in weeks at delivery |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Intravenous Iron Dextran Infusion Women randomized to receive intravenous iron infusion will receive a single infusion of dextran 1000mg IV as an inpatient on the antepartum or Labor & Delivery Unit. They will receive continuous fetal monitoring for 30 minutes before and after the infusion as well for the duration of the infusion
Iron dextran: Single intravenous infusion of iron dextran 1000mg. | 10 |
| Oral Ferrous Sulfate Supplementation Women randomized to continue oral iron will continue to take ferrous sulfate 325mg one to three tablets daily, with the final dose at the discretion of the patient's obstetric provider.
Ferrous sulfate 325mg: Oral iron supplementation with ferrous sulfate 325mg one to three times daily | 13 |
| Total | 23 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 |
|---|---|---|---|
| Overall Study | Withdrawal by Subject | 10 | 5 |
Baseline characteristics
| Characteristic | Total | Intravenous Iron Dextran Infusion | Oral Ferrous Sulfate Supplementation |
|---|---|---|---|
| Age, Continuous | 28 years | 26 years | 28 years |
| Chronic hypertension | 5 Participants | 2 Participants | 3 Participants |
| Ethnicity (NIH/OMB) Hispanic or Latino | 2 Participants | 0 Participants | 2 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 21 Participants | 10 Participants | 11 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants |
| Nulliparous | 4 Participants | 1 Participants | 3 Participants |
| Prepregnancy diabetes | 2 Participants | 1 Participants | 1 Participants |
| Prior preterm birth (<37 weeks' gestation) | 5 Participants | 2 Participants | 3 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Asian | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Black or African American | 21 Participants | 10 Participants | 11 Participants |
| Race (NIH/OMB) More than one race | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) White | 2 Participants | 0 Participants | 2 Participants |
| Region of Enrollment United States | 23 participants | 10 participants | 13 participants |
| Sex: Female, Male Female | 23 Participants | 10 Participants | 13 Participants |
| Sex: Female, Male Male | 0 Participants | 0 Participants | 0 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 0 / 10 | 0 / 13 |
| other Total, other adverse events | 3 / 10 | 3 / 13 |
| serious Total, serious adverse events | 0 / 10 | 0 / 13 |
Outcome results
Maternal Anemia at Delivery
Number of participants with maternal hemoglobin \<11g/dl at delivery
Time frame: At delivery
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Intravenous Iron Dextran Infusion | Maternal Anemia at Delivery | 4 Participants |
| Oral Ferrous Sulfate Supplementation | Maternal Anemia at Delivery | 11 Participants |
APGAR Scores at 1 Minutes of Life
The APGAR score, named after the Virginia Apgar, pediatrician who came up with it, measures the physical condition of a newborn infant on a scale ranging from a minimum of 0 (worsts) to a maximum of 10 (best).
Time frame: Obtained at 1 minute of life
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Intravenous Iron Dextran Infusion | APGAR Scores at 1 Minutes of Life | 8 score on a scale |
| Oral Ferrous Sulfate Supplementation | APGAR Scores at 1 Minutes of Life | 8 score on a scale |
Birth Weight
Neonatal weight at delivery
Time frame: Obtained once, at infant delivery
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Intravenous Iron Dextran Infusion | Birth Weight | 3174.0 grams | Standard Deviation 657.2 |
| Oral Ferrous Sulfate Supplementation | Birth Weight | 3029.2 grams | Standard Deviation 550.5 |
Composite Neonatal Morbidity (Defined by the Occurrence of One or More of 10 Neonatal Morbidities.
Neonatal morbidity composite, defined by the occurrence of one or more of the following neonatal morbidities: neonatal seizures (diagnosed by clinician), intraventricular hemorrhage (diagnosed by clinician on brain MRI or Ultrasound), hypoxic-ischemic encephalopathy (diagnosed by clinician), neonatal hypothermic therapy (brain cooling as documented on inpatient record, sepsis (diagnosed by blood culture), respiratory distress syndrome (diagnosed by clinician), hyperbilirubinemia requiring photo therapy (diagnosed by clinician), birth injury (diagnosed by clinician), or meconium aspiration syndrome (diagnosed by clinician), neonatal intensive care unit admission (documented in the inpatient record).
Time frame: At birth
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Intravenous Iron Dextran Infusion | Composite Neonatal Morbidity (Defined by the Occurrence of One or More of 10 Neonatal Morbidities. | 2 Participants |
| Oral Ferrous Sulfate Supplementation | Composite Neonatal Morbidity (Defined by the Occurrence of One or More of 10 Neonatal Morbidities. | 4 Participants |
Gestational Age at Delivery
Gestational age in weeks at delivery
Time frame: Once, at infant delivery
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Intravenous Iron Dextran Infusion | Gestational Age at Delivery | 38.1 weeks | Standard Deviation 1 |
| Oral Ferrous Sulfate Supplementation | Gestational Age at Delivery | 36.9 weeks | Standard Deviation 2.3 |
Maternal Ferritin at Delivery
Maternal serum ferritin level in μg/L at delivery
Time frame: At delivery
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Intravenous Iron Dextran Infusion | Maternal Ferritin at Delivery | 129.8 μg/L | Standard Deviation 117.2 |
| Oral Ferrous Sulfate Supplementation | Maternal Ferritin at Delivery | 26.6 μg/L | Standard Deviation 14.6 |
Maternal Hemoglobin at Delivery
Maternal hemoglobin on admission to inpatient obstetrics unit for delivery
Time frame: On admission to inpatient obstetrics unit for delivery
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Intravenous Iron Dextran Infusion | Maternal Hemoglobin at Delivery | 11.0 g/dL | Standard Deviation 0.7 |
| Oral Ferrous Sulfate Supplementation | Maternal Hemoglobin at Delivery | 9.9 g/dL | Standard Deviation 1.1 |
Maternal Hemoglobin Below 10g/dl at Delivery
Number of participants with hemoglobin below 10g/dl at delivery
Time frame: At delivery
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Intravenous Iron Dextran Infusion | Maternal Hemoglobin Below 10g/dl at Delivery | 1 Participants |
| Oral Ferrous Sulfate Supplementation | Maternal Hemoglobin Below 10g/dl at Delivery | 7 Participants |
Mode of Delivery
Whether infant was delivered vaginally or via cesarean section
Time frame: Once, at infant delivery
| Arm | Measure | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Intravenous Iron Dextran Infusion | Mode of Delivery | Vaginal delivery | 4 Participants |
| Intravenous Iron Dextran Infusion | Mode of Delivery | Cesarean delivery | 6 Participants |
| Oral Ferrous Sulfate Supplementation | Mode of Delivery | Vaginal delivery | 8 Participants |
| Oral Ferrous Sulfate Supplementation | Mode of Delivery | Cesarean delivery | 5 Participants |
Neonatal Ferritin
Neonatal ferritin in ug/L at delivery
Time frame: Drawn once from umbilical cord segment at birth
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Intravenous Iron Dextran Infusion | Neonatal Ferritin | 169.4 ug/L | Standard Deviation 98.2 |
| Oral Ferrous Sulfate Supplementation | Neonatal Ferritin | 147.1 ug/L | Standard Deviation 69.2 |
Neonatal Hemoglobin
Neonatal hemoglobin in g/dl at delivery
Time frame: Drawn once from umbilical cord segment at birth
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Intravenous Iron Dextran Infusion | Neonatal Hemoglobin | 13.4 g/dL | Standard Deviation 3.4 |
| Oral Ferrous Sulfate Supplementation | Neonatal Hemoglobin | 13.5 g/dL | Standard Deviation 2.1 |
Number of Participants Who Received Blood Transfusion
Participant receiving transfusion of packed red blood cells during admission for delivery of infant obtained via medical chart review.
Time frame: During inpatient admission for delivery of neonate
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Intravenous Iron Dextran Infusion | Number of Participants Who Received Blood Transfusion | 0 Participants |
| Oral Ferrous Sulfate Supplementation | Number of Participants Who Received Blood Transfusion | 2 Participants |
Number of Participants With Medication Adverse Events
Participants reporting symptoms when contacted by via telephone 2 - 3 days after their infusion of intravenous iron or initiation of oral iron
Time frame: 2 - 3 days after single intravenous iron infusion or initiation of oral iron
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Intravenous Iron Dextran Infusion | Number of Participants With Medication Adverse Events | Severe | 0 Participants |
| Intravenous Iron Dextran Infusion | Number of Participants With Medication Adverse Events | Mild/moderate | 3 Participants |
| Oral Ferrous Sulfate Supplementation | Number of Participants With Medication Adverse Events | Severe | 0 Participants |
| Oral Ferrous Sulfate Supplementation | Number of Participants With Medication Adverse Events | Mild/moderate | 3 Participants |
Umbilical Cord Arterial pH
Umbilical cord arterial pH obtained at delivery
Time frame: Drawn once from umbilical cord segment at delivery
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Intravenous Iron Dextran Infusion | Umbilical Cord Arterial pH | 7.24 Unitless | Standard Deviation 0.09 |
| Oral Ferrous Sulfate Supplementation | Umbilical Cord Arterial pH | 7.29 Unitless | Standard Deviation 0.05 |